Toward an oral, once-daily non-peptide STT2 agonist. Paltusotine a novel oral somatostatin receptor 2 (SST2) agonist and Crinetics’ lead investigational drug, is intended to treat acromegaly and neuroendocrine tumors (NETs) in carcinoid syndrome. Both diseases have been treated with surgery and injectable somatostatin [...]
5 minute read
Jan. 28, 2023
Paltusotine: An Oral, Non-Peptide STT2 Agonist
paltusotine
oral, non-peptide SST2 agonist Ph. III for acromegaly + Ph. II for NETs in-house focused library screen + opt. ACS Med. Chem. Lett., December 10, 2022 Crinetics Pharmaceuticals, San Diego, CA
Loading...
